Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Menter

Showing results (161-170 of 298) with videos related to

Pageof 30
Sort By:
Dermatology and Therapy|May 19, 2020
Correction to: Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available EvidenceJashin J Wu, Joseph F Merola, Steven R Feldman, et al.
Journal of the American Academy of Dermatology|January 19, 2016
The spectrum of nephrocutaneous diseases and associations: Genetic causes of nephrocutaneous diseaseJay Wofford, Andrew Z Fenves, J Mark Jackson, et al.
Dermatology and Therapy|November 18, 2019
Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe PsoriasisElsie Grace, Orin Goldblum, Lisa Renda, et al.
Current Medical Research and Opinion|September 14, 2010
Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trialArthur Kavanaugh, Alan Menter, Alan Mendelsohn, et al.
Journal of the American Academy of Dermatology|May 22, 2004
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisChristopher S Carlin, Steven R Feldman, James G Krueger, et al.
International Journal of Dermatology|March 26, 2003
Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacyNick J Lowe, John Gonzalez, Jerry Bagel, et al.
Dermatologic Therapy|November 2, 2020
Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferencesAaminah Azhar, Marcus Zaayman, Annika Silfvast-Kaiser, et al.
Dermatology and Therapy|July 18, 2021
A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment ParadigmBruce Strober, David Pariser, Ann Deren-Lewis, et al.
Journal of the American Academy of Dermatology|December 31, 2005
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasisAlan Menter, Jennifer C Cather, Diane Baker, et al.
Health and Quality of Life Outcomes|October 4, 2008
Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III studyDennis A Revicki, Alan Menter, Steven Feldman, et al.
Pageof 30

Showing results (161-170 of 298) with videos related to

Sort By:
Pageof 30
Dermatology and Therapy|May 19, 2020
Correction to: Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available EvidenceJashin J Wu, Joseph F Merola, Steven R Feldman, et al.
Journal of the American Academy of Dermatology|January 19, 2016
The spectrum of nephrocutaneous diseases and associations: Genetic causes of nephrocutaneous diseaseJay Wofford, Andrew Z Fenves, J Mark Jackson, et al.
Dermatology and Therapy|November 18, 2019
Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe PsoriasisElsie Grace, Orin Goldblum, Lisa Renda, et al.
Current Medical Research and Opinion|September 14, 2010
Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trialArthur Kavanaugh, Alan Menter, Alan Mendelsohn, et al.
Journal of the American Academy of Dermatology|May 22, 2004
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisChristopher S Carlin, Steven R Feldman, James G Krueger, et al.
International Journal of Dermatology|March 26, 2003
Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacyNick J Lowe, John Gonzalez, Jerry Bagel, et al.
Dermatologic Therapy|November 2, 2020
Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferencesAaminah Azhar, Marcus Zaayman, Annika Silfvast-Kaiser, et al.
Dermatology and Therapy|July 18, 2021
A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment ParadigmBruce Strober, David Pariser, Ann Deren-Lewis, et al.
Journal of the American Academy of Dermatology|December 31, 2005
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasisAlan Menter, Jennifer C Cather, Diane Baker, et al.
Health and Quality of Life Outcomes|October 4, 2008
Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III studyDennis A Revicki, Alan Menter, Steven Feldman, et al.
Pageof 30